Pipeline
Development Pipeline
| Candidate | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| ONP-002 | Concussion / mTBI | ✓ | ✓ | Active | — |
Phase 1 Complete
Safe and well-tolerated across all dose levels; zero serious adverse events
Phase 2a Active
40-patient randomized, placebo-controlled trial underway in Australia
Platform Technology: Beyond ONP-002
While ONP-002 leads our pipeline for concussion treatment, our proprietary intranasal delivery platform has applications across multiple neurological conditions. Through our partnership with Receptor.AI, we are accelerating AI-driven exploration of additional indications.
Non-invasive
No pills, no injections — nasal spray administration
Rapid onset
Direct-to-brain delivery enables faster therapeutic action
Reduced systemic exposure
Targeted delivery minimizes side effects common with systemic drugs
Field-ready design
Portable, single-use device suitable for emergency and sports settings
Platform technology potentially applicable to:
PTSD
Stroke
Seizures
Alzheimer’s Disease
Parkinson’s Disease
Other CNS disorders
The nasal drug delivery market is projected to exceed $125 billion by 2030, with neurological applications representing one of the fastest-growing segments.
Learn More
Explore our lead asset in detail or connect with our investor relations team.